Company Filing History:
Years Active: 2009-2010
Title: **Selim Kuci: Innovator in Monoclonal Antibody Research**
Introduction
Selim Kuci, based in Tuebingen, Germany, is a notable inventor recognized for his contributions in the field of biotechnology. With a focus on developing monoclonal antibodies, Kuci has made significant strides in identifying and isolating various cell populations, indicating his vital role in advancing scientific research and medical applications.
Latest Patents
Selim Kuci holds two patents that reflect his innovative approach to monoclonal antibodies. His latest patents detail antibodies for identifying and/or isolating specific cell populations, including haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells, and mesenchymal progenitor cells. These inventions emphasize the ability of these antibodies, or their fragments, to bind to antigens similar to those recognized by antibodies from hybridoma cell lines CUB1, CUB2, CUB3, and CUB4. The hybridoma cell lines were deposited in the DSMZ under the specified accession numbers, facilitating further research and development in cellular biology.
Career Highlights
Kuci is affiliated with Hoffmann-La Roche Inc., a global leader in pharmaceuticals and diagnostics. His work at this esteemed company allows him to engage in innovative research that directly impacts therapeutic development and the understanding of various diseases. His inventiveness and dedication have positioned him as a key player in his field.
Collaborations
Throughout his career, Selim Kuci has collaborated with esteemed colleagues such as Hans-Joerg Buehring and Reiner Lammers. These partnerships have fostered a conducive environment for innovation and have enabled them to tackle complex challenges in the realm of biotechnology.
Conclusion
In conclusion, Selim Kuci's contributions to the development of monoclonal antibodies signify a pivotal advancement in the identification and isolation of critical cell populations. His work at Hoffmann-La Roche Inc. and collaborations with fellow innovators highlight his commitment to scientific discovery and the continued progression of biomedical research.